FDA: Doctors should use genetic test before prescribing abacavir

07/24/2008 | NYTimes.com

The FDA is expected to release an advisory today that calls on doctors to use a genetic test before prescribing abacavir -- sold by GlaxoSmithKline under the name Ziagen -- to prevent severe allergic reactions in patients carrying an immune-system gene variant. The recommendation will be included in a "black box" warning on Ziagen's new label, which will also mention the increased risk of heart attack based on "inconclusive" study data.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Director of Litigation
Center for Science in the Public Interest
Washington, DC
Health Plan CEO - Oregon
Trillium Community Health Plan
Eugene, OR
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC